Zelenetz, Andrew

Publications

Sort by

Co-Author Network

selected publications

Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. Leukemia. 2020 Letter GET IT
Times cited: 7
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood advances. 2019 Academic Article GET IT
Times cited: 21
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. The Lancet. Haematology. 2019 Academic Article GET IT
Times cited: 45
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 156
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 208
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2018 Academic Article GET IT
Times cited: 72
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leukemia & lymphoma. 2018 Academic Article GET IT
Times cited: 14
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood cancer journal. 2018 Academic Article GET IT
Times cited: 22
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 Academic Article GET IT
Times cited: 117
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1068
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood. 2018 Academic Article GET IT
Times cited: 47
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 85
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. 2017 GET IT
Times cited: 47
Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. British journal of haematology. 2016 Academic Article GET IT
Times cited: 37
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. Journal of the National Comprehensive Cancer Network : JNCCN. 2016 Academic Article GET IT
Times cited: 7
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. 2016 GET IT
Times cited: 101
[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 7
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 54
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016 Academic Article GET IT
Times cited: 152
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica. 2016 Academic Article GET IT
Times cited: 32
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. American journal of hematology. 2016 Academic Article GET IT
Times cited: 18
The Role of Biosimilars. Journal of the National Comprehensive Cancer Network : JNCCN. 2016 Academic Article GET IT
Times cited: 6
Central nervous system involvement in T-cell lymphoma: A single center experience. Acta oncologica (Stockholm, Sweden). 2016 Academic Article GET IT
Times cited: 34
The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 Review GET IT
Times cited: 4848
Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Human molecular genetics. 2016 Academic Article GET IT
Times cited: 44
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months. British journal of haematology. 2016 Academic Article GET IT
Times cited: 11
Diffuse Large B-Cell Lymphoma Version 1.2016. Journal of the National Comprehensive Cancer Network : JNCCN. 2016 Academic Article GET IT
Times cited: 68
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 Academic Article GET IT
Times cited: 33
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Cancer. 2015 Academic Article GET IT
Times cited: 54
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Academic Article GET IT
Times cited: 212
Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. British journal of haematology. 2015 Academic Article GET IT
Times cited: 25
Acute Lymphoblastic Leukemia, Version 2.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Academic Article GET IT
Times cited: 74
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 20
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 130
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic proceedings. 2015 Academic Article GET IT
Times cited: 122
Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. Bone marrow transplantation. 2015 Academic Article GET IT
Times cited: 16
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 514
Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. Radiology. 2015 Academic Article GET IT
Times cited: 23
Management of adverse events associated with idelalisib treatment: expert panel opinion. Leukemia & lymphoma. 2015 Review GET IT
Times cited: 247
Emerging treatment options for B-cell lymphomas. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Academic Article GET IT
Times cited: 2
NCCN Roundtable: What Are the Characteristics of an Optimal Clinical Practice Guideline?. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Academic Article GET IT
Times cited: 10
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. British journal of haematology. 2015 Academic Article GET IT
Times cited: 45
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015 Academic Article GET IT
Times cited: 94
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. 2015 GET IT
Times cited: 45
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 201
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2014 Academic Article GET IT
Times cited: 30
Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy. 2014 GET IT
Times cited: 5
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. British journal of haematology. 2014 Academic Article GET IT
Times cited: 29
Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature genetics. 2014 Review GET IT
Times cited: 124
Non-Hodgkin's lymphomas, version 4.2014. 2014 GET IT
Times cited: 100
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 46
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Academic Article GET IT
Times cited: 345
Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma. PloS one. 2014 Academic Article GET IT
Times cited: 16
Non-Hodgkin's lymphomas, version 2.2014. 2014 GET IT
Times cited: 56
Guidelines for NHL: updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Editorial Article GET IT
Times cited: 21
International adaptation and use of NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Editorial Article GET IT
Times cited: 1
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. 2014 Academic Article GET IT
Times cited: 31
Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells. PloS one. 2014 Academic Article GET IT
Times cited: 9
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. British journal of haematology. 2014 Academic Article GET IT
Times cited: 70
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 1408
Surveillance imaging for lymphoma: pros and cons. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2014 Review GET IT
Times cited: 10
Association of quantitative assessment of the intrafollicular proliferation index with outcome in follicular lymphoma. British journal of haematology. 2013 Academic Article GET IT
Times cited: 8
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 31
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2013 Academic Article GET IT
Times cited: 612
False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 19
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. British journal of haematology. 2013 Academic Article GET IT
Times cited: 57
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 36
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 2013 Academic Article GET IT
Times cited: 54
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature genetics. 2013 Review GET IT
Times cited: 152
Recent advances in the treatment of non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network : JNCCN. 2013 Review GET IT
Times cited: 8
18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leukemia & lymphoma. 2013 Academic Article GET IT
Times cited: 54
Non-Hodgkin's lymphomas, version 1.2013. 2013 GET IT
Times cited: 52
Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leukemia & lymphoma. 2013 Academic Article GET IT
Times cited: 11
Indications for and efficacy of splenectomy for haematological disorders. The British journal of surgery. 2013 Academic Article GET IT
Times cited: 18
The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma. European journal of nuclear medicine and molecular imaging. 2013 Academic Article GET IT
Times cited: 2
Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS genetics. 2013 Academic Article GET IT
Times cited: 42
Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clinical lymphoma, myeloma & leukemia. 2012 Academic Article GET IT
Times cited: 224
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 163
Non-Hodgkin's Lymphomas, version 3.2012. Journal of the National Comprehensive Cancer Network : JNCCN. 2012 Academic Article GET IT
Times cited: 31
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clinical lymphoma, myeloma & leukemia. 2012 Academic Article GET IT
Times cited: 58
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 67
Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2012 Review GET IT
Times cited: 34
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 122
Acute lymphoblastic leukemia. 2012 GET IT
Times cited: 50
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 33
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012 Academic Article GET IT
Times cited: 84
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2011 Academic Article GET IT
Times cited: 226
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2011 Academic Article GET IT
Times cited: 147
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2011 Academic Article GET IT
Times cited: 71
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. Journal of the National Comprehensive Cancer Network : JNCCN. 2011 Conference Paper GET IT
Times cited: 121
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. The Journal of experimental medicine. 2011 Academic Article GET IT
Times cited: 96
Electronic Chemotherapy Order Entry: A Major Cancer Center's Implementation. Journal of oncology practice. 2011 Academic Article GET IT
Times cited: 14
Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leukemia & lymphoma. 2011 Conference Paper GET IT
Times cited: 33
Non-Hodgkin's lymphomas. 2011 GET IT
Times cited: 56
Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 37
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 25
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. British journal of cancer. 2010 Academic Article GET IT
Times cited: 117
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010 Academic Article GET IT
Times cited: 203
Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region. 2010 GET IT
Times cited: 4
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 269
An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2010 Review GET IT
Times cited: 24
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. 2010 GET IT
Times cited: 200
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. British journal of haematology. 2010 Academic Article GET IT
Times cited: 80
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 43
Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 63
Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2009 Academic Article GET IT
Times cited: 33
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 27
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 166
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British journal of haematology. 2009 Academic Article GET IT
Times cited: 49
NCCN task force report: molecular markers in leukemias and lymphomas. Journal of the National Comprehensive Cancer Network : JNCCN. 2009 Review GET IT
Times cited: 9
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. British journal of haematology. 2009 Academic Article GET IT
Times cited: 130
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 Academic Article GET IT
Times cited: 785
Follicular lymphoma in the United States: first report of the national LymphoCare study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 241
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. British journal of haematology. 2009 Academic Article GET IT
Times cited: 68
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone marrow transplantation. 2009 Academic Article GET IT
Times cited: 47
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 62
Synchronous presentation of systemic and brain non-Hodgkin lymphoma. Leukemia & lymphoma. 2008 Letter GET IT
Times cited: 2
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 72
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 18
Hodgkin disease/lymphoma. 2008 GET IT
Times cited: 5
Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. Clinical advances in hematology & oncology : H&O. 2008 Review GET IT
Times cited: 7
Non-Hodgkin's lymphomas. 2008 GET IT
Times cited: 17
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 42
Overview of lymphoma diagnosis and management. Radiologic clinics of North America. 2008 Review GET IT
Times cited: 94
Treatment of follicular lymphoma: current status. Leukemia & lymphoma. 2008 Review GET IT
Times cited: 10
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer. 2007 Academic Article GET IT
Times cited: 39
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. British journal of haematology. 2007 Academic Article GET IT
Times cited: 79
Will radioimmunotherapy survive?. Clinical advances in hematology & oncology : H&O. 2007 Academic Article GET IT
Times cited: 2
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 33
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2007 Academic Article GET IT
Times cited: 103
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 229
Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leukemia & lymphoma. 2007 Academic Article GET IT
Times cited: 69
FDG-PET lymphoma demonstration project invitational workshop. Academic radiology. 2007 Academic Article GET IT
Times cited: 25
Automated matching and segmentation of lymphoma on serial CT examinations. Medical physics. 2007 Academic Article GET IT
Times cited: 13
Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression. Cytogenetic and genome research. 2007 Academic Article GET IT
Times cited: 17
Marker-controlled watershed for lymphoma segmentation in sequential CT images. Medical physics. 2006 Academic Article GET IT
Times cited: 61
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. British journal of haematology. 2006 Academic Article GET IT
Times cited: 104
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Academic Article GET IT
Times cited: 93
Mantle cell lymphoma: an update on management. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Review GET IT
Times cited: 26
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 142
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. 2006 GET IT
Times cited: 28
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. 2006 GET IT
Times cited: 32
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 373
Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood. 2005 Academic Article GET IT
Times cited: 73
Proteasome inhibitors in non-Hodgkin's lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2005 Academic Article GET IT
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 217
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. British journal of haematology. 2005 Academic Article GET IT
Times cited: 109
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood. 2005 Academic Article GET IT
Times cited: 72
Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 14
R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leukemia & lymphoma. 2005 Academic Article GET IT
Times cited: 39
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005 Academic Article GET IT
Times cited: 155
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 546
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 133
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Academic Article GET IT
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Academic Article GET IT
Times cited: 16
Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma. Applied immunohistochemistry & molecular morphology : AIMM. 2004 Academic Article GET IT
Times cited: 6
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004 Academic Article GET IT
Times cited: 232
Non-Hodgkin's lymphoma clinical practice guidelines. 2004 GET IT
Times cited: 3
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. British journal of haematology. 2004 Academic Article GET IT
Times cited: 61
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. British journal of haematology. 2004 Academic Article GET IT
Times cited: 147
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004 Academic Article GET IT
Times cited: 349
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 254
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood. 2003 Academic Article GET IT
Times cited: 83
Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma. Oncology (Williston Park, N.Y.). 2003 Review GET IT
Times cited: 7
Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone marrow transplantation. 2003 Academic Article GET IT
Times cited: 95
Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003 Academic Article GET IT
Times cited: 134
Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leukemia & lymphoma. 2003 Academic Article GET IT
Times cited: 104
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003 Academic Article GET IT
Times cited: 220
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. Seminars in oncology. 2003 Review GET IT
Times cited: 51
MUC-1 mucin protein expression in B-cell lymphomas. Applied immunohistochemistry & molecular morphology : AIMM. 2003 Academic Article GET IT
Times cited: 12
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2003 Academic Article GET IT
Times cited: 106
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Review GET IT
Times cited: 98
Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma. Genes, chromosomes & cancer. 2002 Academic Article GET IT
Times cited: 48
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002 Academic Article GET IT
Times cited: 30
Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. Blood. 2002 Academic Article GET IT
Times cited: 43
Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Cancer journal (Sudbury, Mass.). 2002 Academic Article GET IT
Times cited: 22
Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene. 2001 Academic Article GET IT
Times cited: 34
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 543
Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. Blood. 2001 Academic Article GET IT
Times cited: 26
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001 Academic Article GET IT
Times cited: 374
Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leukemia & lymphoma. 2001 Academic Article GET IT
Times cited: 64
Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma. 2001 GET IT
Times cited: 12
NCCN: Non-Hodgkin's lymphoma. Cancer control : journal of the Moffitt Cancer Center. 2001 Conference Paper GET IT
Times cited: 17
Cloning and characterization of a Golgin-related gene from the large-scale polymorphism linked to the PML gene. Genomics. 2000 Academic Article GET IT
Times cited: 11
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood. 2000 Academic Article GET IT
Times cited: 120
Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia. 2000 Academic Article GET IT
Times cited: 40
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy. Leukemia & lymphoma. 2000 Academic Article GET IT
Times cited: 17
MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma. Blood. 2000 Academic Article GET IT
Times cited: 45
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 331
A novel gene STORP (STOmatin-Related Protein) is localized 2 kb upstream of the promyelocytic gene on chromosome 15q22. European journal of haematology. 2000 Academic Article GET IT
Times cited: 6
Physical linkage of the lysyl oxidase-like (LOXL1) gene to the PML gene on human chromosome 15q22. Cytogenetics and cell genetics. 2000 Academic Article GET IT
Times cited: 4
Translocation t(14;18) in healthy individuals: preliminary study of its association with family history and agricultural exposure. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Academic Article GET IT
Times cited: 23
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Times cited: 275
The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154 kb upstream of Kit. Blood. 1999 Academic Article GET IT
Times cited: 55
Radioimmunotherapy for lymphoma. Current opinion in oncology. 1999 Review GET IT
Times cited: 52
NCCN practice guidelines for Hodgkin's disease. National Comprehensive Cancer Network. 1999 GET IT
Times cited: 15
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone marrow transplantation. 1999 Academic Article GET IT
Times cited: 60
Emerging role of laparoscopy in the diagnosis of lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 28
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 121
Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. Proceedings of the National Academy of Sciences of the United States of America. 1998 Academic Article GET IT
Times cited: 61
NCCN preliminary non-Hodgkin's lymphoma practice guidelines. Oncology (Williston Park, N.Y.). 1997 Academic Article GET IT
Times cited: 14
Microsatellite instability in breast cancer. Annals of surgical oncology. 1997 Academic Article GET IT
Times cited: 17
Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 1997 Academic Article GET IT
Times cited: 23
The AML1/ETO fusion protein activates transcription of BCL-2. Proceedings of the National Academy of Sciences of the United States of America. 1996 Academic Article GET IT
Times cited: 167
Derivation and characterization of retinoid-resistant human embryonal carcinoma cells. Differentiation; research in biological diversity. 1996 Academic Article GET IT
Times cited: 21
BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. Leukemia & lymphoma. 1995 Academic Article GET IT
Times cited: 32
A novel L23-related gene 40 kb downstream of the imprinted H19 gene is biallelically expressed in mid-fetal and adult human tissues. Human molecular genetics. 1995 Academic Article GET IT
Times cited: 37
The Wsh and Ph mutations affect the c-kit expression profile: c-kit misexpression in embryogenesis impairs melanogenesis in Wsh and Ph mutant mice. Proceedings of the National Academy of Sciences of the United States of America. 1995 Academic Article GET IT
Times cited: 81
The PML gene is linked to a megabase-scale insertion/deletion restriction fragment length polymorphism. Genomics. 1995 Academic Article GET IT
Times cited: 12
Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). 1995 GET IT
Times cited: 308
Mucosa-associated lymphoid-tissue lymphoma. The New England journal of medicine. 1993 Letter GET IT
Times cited: 1
Pulsed-field gel electrophoresis analysis of retinoic acid receptor-alpha and promyelocytic leukemia rearrangements. Detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia. The American journal of pathology. 1993 Academic Article GET IT
Times cited: 10
W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. Development (Cambridge, England). 1993 Academic Article GET IT
Times cited: 121
A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma. Genes, chromosomes & cancer. 1993 Academic Article GET IT
Times cited: 23
Antigen selection in human lymphomagenesis. Cancer research. 1992 Review GET IT
Times cited: 28
Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. The Journal of experimental medicine. 1992 Academic Article GET IT
Times cited: 153
BCL2 oncogene translocation is mediated by a chi-like consensus. The Journal of experimental medicine. 1992 Academic Article GET IT
Times cited: 107
Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Molecular immunology. 1992 Academic Article GET IT
Times cited: 171
Construction of complex directional complementary DNA libraries in SfiI. Methods in enzymology. 1992 Academic Article GET IT
Times cited: 3
Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. Blood. 1991 Academic Article GET IT
Times cited: 18
Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. Blood. 1991 Academic Article GET IT
Times cited: 73
Follicular lymphoma: a model of lymphoid tumor progression in man. Annals of oncology : official journal of the European Society for Medical Oncology. 1991 Review GET IT
Times cited: 14
Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell. The Journal of experimental medicine. 1991 Academic Article GET IT
Times cited: 100
Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood. 1990 Academic Article GET IT
Times cited: 29
Regulation of ribosome synthesis during compensatory renal hypertrophy in mice. The American journal of physiology. 1987 Academic Article GET IT
Times cited: 13
Molecular cloning and characterization of the chicken gene homologous to the transforming gene of Rous sarcoma virus. Cell. 1981 Academic Article GET IT
Times cited: 52
Transformation by subgenomic fragments of Rous sarcoma virus DNA. Cell. 1980 Academic Article GET IT
Times cited: 25
Transformation of NIH-3T3 mouse cells by avian retroviral DNAs. Cold Spring Harbor symposia on quantitative biology. 1980 Academic Article GET IT
Times cited: 3
Transformation of NIH/3T3 mouse cells by DNA of Rous sarcoma virus. Cell. 1979 Academic Article GET IT
Times cited: 46
gltB gene and regulation of nitrogen metabolism by glutamine synthetase in Escherichia coli. Journal of bacteriology. 1978 Academic Article GET IT
Times cited: 57
Circadian periodicity of epidermal growth factor and its abolition by superior cervical ganglionectomy. Endocrinology. 1976 Academic Article GET IT
Times cited: 36

more ...

less ...

Background

education and training

M.D., Harvard Medical School 1984
Ph.D., Harvard University 1984
A.B., Harvard University 1977

Contact

full name

Andrew Zelenetz

VIVO Weill Cornell Medical College

Andrew Zelenetz Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name